Version: 31.08.2011 Supersedes: 26.03.2009

PREGNANCY OUTCOME REPORT FORM PART 2 – OUTCOME REPORT

RS-F-11B.3E/RS-F-6GB.2E

Page: 1/2

Please return this form to Lipomed AG, Fabrikmattenweg 4, CH-4144 Arlesheim, Switzerland by mail (save@lipomed.com) or fax (Fax No. +41 61 702 02 20)

PATIENT DATA
Initials: Birth date:
Body surface area: Weight: Height: Height:
OUTCOME OF PREGNANCY
day month year Date:
☐ Live birth ☐ Spontaneous abortion ☐ Induced abortion ☐ Other, please specify
NEWBORN
Gestational age: weeks
Delivery complications: no yes if yes, please specify
Sex: □ F♀ □ M♂
Weight:
Height:
Healthy infant?
APGAR-Score: At 1 minute:At 5 minutes:At 10 minutes:
Other comments (e. g. disease during pregnancy, further prenatal diagnostics):

Date: 31.08.2011 Issued: J. Goldschmidt

Date: Reviewed: Dr. M. Bernstein Date:

QA-approved: D. Foechterlen

Version: 31.08.2011

PREGNANCY OUTCOME REPORT FORM PART 2 – OUTCOME REPORT

RS-F-11B.3E/RS-F-6GB.2E
Page: 2/2

Supersedes: 26.03.2009 PART 2 – OUTCO

FURTHER MEDICATION DURING PREGNANCY Trade name/ Lot. No. Expiry Route of Daily dose Therapy dates Indication(s) for use Drug name date adminisfrom tration Complications / Adverse events occurred during pregnancy? ☐ no yes if yes, please fill in the separate Adverse Event Report Form which will be sent to you **QUALIFIED REPORTING PERSON** Name: Address: Postal code: City: Country: State: Telephone: Profession: OK to report your name to local Health Authority? yes no Was report submitted to local Health Authority? □ ves □ no If yes, please specify authority: dav Signature: Date: SUBMISSION OF A REPORT DOES NOT NECESSARILY CONSTITUTE A JUDGEMENT THAT THE DRUG **CAUSED THE ADVERSE EVENT.** Will be completed by Lipomed AG or local monitor only: Company data: Report source: Status: Reported to health authorities: National organization: Market Initial Yes Contact person: Health Professional Follow-up No Signature: Consumer Other: Date: Health Authority Date report was received by Literature company: Study Study number: Date: Patient number:

Date: 31.08.2011 Date: Date:

Issued: J. Goldschmidt Reviewed: Dr. M. Bernstein QA-approved: D. Foechterlen